There is no screening test for botulism and no professional-society or U.S. Preventive Services Task Force (USPSTF) recommendation for screening asymptomatic individuals; USPSTF has never issued a botulism screening statement. Botulism is a rare, acute, non-communicable intoxication that does not have an asymptomatic or preclinical detectable phase amenable to screening; it therefore fails standard screening (Wilson-Jungner) criteria. Instead of screening, the relevant public-health activities are mandatory case reporting, surveillance, rapid clinical recognition, and outbreak case-finding, with close observation (not laboratory screening) of asymptomatic exposed persons.^[1][2]

Botulism does not meet the conditions that make screening useful:^[3][4]

• No detectable asymptomatic/latent phase in which early detection would change outcome; disease is defined by acute neurologic signs.
• Very low prevalence (a few hundred U.S. cases/year across all forms), which would render any screening test’s positive predictive value negligible.
• Confirmatory tests are slow and reference-laboratory–based (mouse bioassay, mass spectrometry, NAAT for BoNT genes) and are designed to confirm clinically suspected disease, not to screen well people.
• Diagnosis is clinical and treatment is empiric: antitoxin is given on clinical suspicion without waiting for testing, so a screening paradigm offers no benefit.

• Mandatory reporting. Botulism of any type is a nationally notifiable condition; in most U.S. jurisdictions a case suspected on clinical grounds alone must, by law, be reported immediately (by telephone) to local/state health authorities. State health departments maintain 24-hour service, and the CDC Clinical Emergency Botulism Service is available at 770-488-7100.^[5][6]
• National surveillance. Since 1973 the CDC has maintained national botulism surveillance; because antitoxin is released only through public-health channels, nearly all recognized cases are captured, supporting outbreak detection and trend monitoring.^[7]
• Heightened clinical detection. CDC outbreak guidance provides a diagnostic tool and urges clinicians to consider botulism in patients labeled as myasthenia gravis, Guillain-Barré syndrome, or isolated symmetric facial/bulbar weakness, and to watch for early respiratory failure—an approach that functions as active case detection during outbreaks.^[8]
• Newborn screening. Botulism is not included in newborn screening programs; infant botulism is identified by clinical recognition and confirmatory testing of symptomatic infants, not by screening.^[9]
• Outbreak case-finding. Once one case is identified, public-health investigation actively seeks additional exposed persons (e.g., shared food source), collects implicated foods, and obtains serum/stool from co-exposed symptomatic persons—case-finding, not asymptomatic screening.^[10]

Asymptomatic persons known to have ingested a food containing (or suspected of containing) botulinum toxin should not undergo prophylactic antitoxin; instead they require close medical observation in nonsolitary settings for evolving signs. This is active surveillance of a defined exposed cohort, distinct from population screening.^[11][12]

Because there is no screening, risk reduction depends on primary prevention (no honey before 12 months; safe home-canning/pressure processing; adequate refrigeration of processed foods; harm reduction for injection drug use), which is addressed in the Primary Prevention microchapter and only cross-referenced here.^[13][14]

• Do not order botulism toxin testing to screen asymptomatic people; test only symptomatic patients, and treat on clinical suspicion without awaiting results.^[15]
• Report any suspected case immediately to the state health department (or CDC after hours); reporting substitutes for screening as the population-level safeguard.^[16]
• Observe, do not prophylactically treat, asymptomatic exposed persons in a monitored, nonsolitary setting.^[17]